Metal complexes as inhibitors of the 26S proteasome in tumor cells
- PMID: 22112841
- DOI: 10.1016/j.jinorgbio.2011.09.003
Metal complexes as inhibitors of the 26S proteasome in tumor cells
Abstract
The ubiquitin/proteasome pathway is the main mechanism available for eukaryotic cells to eliminate defective proteins and enzymes. Tumor cells -particularly those in solid tumors such as prostate cancer- seem to display increased proteasomal activity associated to cell growth. When such activity is inhibited apoptotic cell death takes place. Thus, the understanding of the chemical mechanisms by which this inhibition occurs is relevant to the development of new therapeutic antineoplastic agents. Here a short review is presented on the synthesis, characterization, and activity of metal-containing species with asymmetric ligands containing the methylpyridin-amino-methylphenol moiety. These complexes were scrupulously investigated structurally and spectroscopically, and have been shown to inhibit the chymotrypsin-like activity of the 20S and 26S proteasome in vitro and in vivo. Recent developments in the understanding of such inhibition are discussed and point out to the influence exerted by ligand substituents, the electronic configurations and charges of the metal ion, and the role of counterions.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects.Cancer Res. 2007 Oct 1;67(19):9258-65. doi: 10.1158/0008-5472.CAN-07-1813. Cancer Res. 2007. PMID: 17909033
-
Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10. J Nucl Med. 2012. PMID: 23055533
-
Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.Cancer Res. 2002 Dec 1;62(23):6901-8. Cancer Res. 2002. PMID: 12460905
-
Targeting the ubiquitin+proteasome system in solid tumors.Semin Hematol. 2012 Jul;49(3):277-83. doi: 10.1053/j.seminhematol.2012.04.002. Semin Hematol. 2012. PMID: 22726552 Review.
-
Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).Mol Med Rep. 2017 Jan;15(1):3-11. doi: 10.3892/mmr.2016.6022. Epub 2016 Dec 9. Mol Med Rep. 2017. PMID: 27959411 Review.
Cited by
-
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.Sci Rep. 2014 Jun 10;4:5240. doi: 10.1038/srep05240. Sci Rep. 2014. PMID: 24912524 Free PMC article.
-
A Comprehensive Review of the Biological Activities of Medicinal Metal Complexes Synthesized From Quinoline Scaffolds.Bioinorg Chem Appl. 2025 Feb 11;2025:3133615. doi: 10.1155/bca/3133615. eCollection 2025. Bioinorg Chem Appl. 2025. PMID: 39968347 Free PMC article. Review.
-
Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. doi: 10.1517/13543776.2015.1056737. Epub 2015 Jun 16. Expert Opin Ther Pat. 2015. PMID: 26077642 Free PMC article. Review.
-
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.J Hematol Oncol. 2016 Nov 25;9(1):129. doi: 10.1186/s13045-016-0359-x. J Hematol Oncol. 2016. PMID: 27884201 Free PMC article.
-
The protease DDI2 regulates NRF1 activation in response to cadmium toxicity.iScience. 2022 Sep 27;25(10):105227. doi: 10.1016/j.isci.2022.105227. eCollection 2022 Oct 21. iScience. 2022. PMID: 36248746 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources